Dr Boreham’s Crucible: Oh, Mesoblast! You were the Chosen One!
The US Food and Drug Administration (FDA) adjudication on Mesoblast’s (ASX:MSB) graft versus host disease (GvHD) therapy was a bombshell for both the long-suffering company and the life sciences sector as whole.
To management’s chagrin, the FDA knocked back the company’s marketing application to sell its lead candidate, remestemcel-L, in the US for paediatric GvHD.
Assent would have marked the first commercial product for Mesoblast in a major market and endorsed its stem-cell science for other indications including back pain and heart disease.
Strictly speaking, the FDA says it requires more supportive data and has told the company to do a phase III trial. The company has resolved to do that, albeit with highest-need adult patients.
The so-called Biologics License Application (BLA) was Mesoblast’s second attempt: the FDA rejected a similar entreaty in 2020, despite an advisory committee voting nine to one in favour of approval.
“It is clear they [the FDA] would like additional data to get the comfort the product continues to demonstrate survival benefits in the hardest-to-treat, highest-risk patients,” Mesoblast founder and CEO Silviu Itescu said on Friday.
He added: “we remain steadfast in making remestemcel-L available to both children and adults suffering from this devastating disease and have received substantial clarity on how to bring this much-needed product to these patients.”
Investors took a less charitable view, slicing 56 percent, or half a billion dollars from the value of Mesoblast shares and sending them to a 22-year low.
The breakthrough approval follows Mesoblast’s setbacks with its heart, back pain and Covid-19 programs, while its Nasdaq listing failed to deliver the expected value uplift.
When the FDA rejected the company’s application in 2020, the agency told the company at the time to do another trial.
A baffled Dr Itescu said the company went through a prolonged “resolution process”, in which the FDA asked for improved potency assays and the like – but dropped the trial requirements.
The agency found no safety issues with the 1300 patients treated with the therapy to date.
FDA inspectors also visited Mesoblast’s Singapore stem cell manufacturing operations and found no outstanding issues.
“We had fully anticipated the additional clinical data including long-term survival benefits would be sufficient to allow a sequenced approach to the market,” Dr Itescu says.
‘Sequenced’ refers to kids first, adults next.
Bell Potter analyst John Hester remarked: “It seems the FDA keeps moving the goalposts here.”
About 80 percent of GvHD sufferers are adults. Usually associated with bone marrow recipients suffering blood cancers, GvHD is usually treated with steroids but this treatment is ineffective for many patients.
Mesoblast’s tech derived from tech developed over ten years by the Institute of Medical and Veterinary Sciences and the Hanson Institute in Adelaide.
Prof Itescu had founded Angioblast Systems Inc, which specialised in heart stem cell therapies.
Mesoblast listed on the ASX in December 2004, having raised $21 million at 50 cents apiece and then on the Nasdaq in late 2015.
Mesoblast also acquired one-third of Angioblast at the time of the IPO and mopped up the remainder in 2010.
In another seminal deal it bought the intellectual property of US pharma group Osiris Therapeutics in 2013, for around $US20 million (plus milestones). Crucially, this delivered the GvHD indication.
The company receives royalties or milestones on two non-US approved products: for GvHD in Japan (Temcell, marketed by JCR Pharmaceuticals) and for perianal fistulas in Europe (Alofisel, marketed by Tigenix). Perianal fistulas are a common complication of Crohn’s disease.
As we mentioned, the GvHD program pertain to the mesenchymal stem cell (MSC) platform, acquired from US pharma group Osiris Therapeutics in 2013.
Prof Itescu’s original tech was something else called ‘own’ mesenchymal precursor cells, relevant for ailments including congestive heart failure, lower back pain, and arthritis to (previously) diabetes.
Using a proprietary process, Mesoblast selects precursor and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell kitty is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast is targeting a common market across all its disease indications: inflammation.
In the case of heart disease, tissue macrophages churn out inflammatory factors that damage heart muscle, cause fibrosis and vascular dysfunction.
Graft-versus-host disease (GvHD) affects about half of all allogeneic (off-the-shelf) bone marrow transplant recipients, affecting the skin, liver and gastrointestinal tract.
There are more than 30,000 bone marrow transplants annually, about 6000 in kids (1500 of them in the US)
In the case of patients resistant to the standard of care of steroids, mortality rates are as high as 90 per cent.
The company carried out three paediatric trials which in effect showed remestemcel-L improved what Mr Itescu dubs the “dismal survival” of kids with chronic forms of the disorder.
The data from 51 patients showed a 51 percent survival rate at year two, compared with 35 percent for the standard of care.
Mesoblast plans a so-called Type A meeting with the FDA within the next 45 days to nut out the size and scope of the adult trial.
Dr Itescu can’t provide too much detail until then, but says the trial will cover as many as 40 US sites. Given the participants will not have responded to treatment and are very ill, there will not be a placebo arm.
As for the cost, the company is working with academic parties in the bone marrow space to share the funding burden and access available inventory (bone marrow samples).
“We expect this to be funded as a bone marrow study,” he says.
Dr Itescu notes the intended patients have a 90-day survival rate as low as 20-30 percent, whereas adult emergency use of the stem-cell therapy showed much better outcomes.
Mesoblast’s heart program has been plagued by setbacks, but it is still beating.
In 2018 a phase III, 159-patient investigator-led trial of Revascor (rexlemestrocel-L) for chronic heart failure failed to reach its primary endpoint of temporarily weaning patients from left-ventricle assist devices (LVADs).
In 2016 partner Teva had walked away from a deal by which it would have funded the heart program (sending Mesoblast shares down 42 percent in a day).
In 2020 a 537-patient heart trial, Dream-HF also failed to reach its primary endpoint of reducing heart failure events in chronic heart failure patients. But that’s not the end of the story (see below).
Dubbed DREAM-HF, the randomised, double blinded, placebo-controlled effort showed that MSCs strengthened heart function at 12 months.
This was measured by left ventricle ejection fraction – how much blood the heart spurts – and decreased deaths from myocardial infarction and stroke over a 30 month follow up.
This was in relation to New York Heart Association (NYHA) class II and class III patients – the third worst category out of four. Of the 301 patients with high inflammation, the efficacy increased to 45 percent.
Having been granted FDA assent to do so, Mesoblast now plans to launch two follow-up phase III trials for class II-III and late-stage patients on death’s door.
Mesoblast also has permission to second pivotal phase III trial for chronic lower back pain, which affects about 30 million Americans and 40 million Europeans and really is … a pain.
In February 2021, a 404-patient phase III trial of rexlemestrocel-L for chronic lower back pain caused by disc degeneration also failed to meet its primary endpoints, but showed the therapy provided a “safe, durable and effective” alternative, with best results when dispensed early in treatment.
A key motivator is that a whopping 50 percent of US opioid prescriptions are for chronic back pain, Of the 168 patients prescribed opioids, there was a 40 percent reduction in opioid use over this period.
The new phase III trial will be testing rexlemestrocel-L alongside the standard of care of hyaluronic acid. The company hopes to start enrolling across US and European sites in the current quarter.
Mesoblast has a knack of raising money when it needs it and sure enough the company in April 2023 it rustled up $US40 million via a placement.
The book was filled by mainly existing local and offshore investors.
In August last year the company raised $US45 million, also in a placement, backed by British fund manager M&G Investments which became a substantial holder.
The company reported receipts of $US1.834 million in the June 2023 quarter, derived mainly from Japan from Temcell royalties. Total receipts for the year were $US7.48 million.
Cash burn for the quarter was $US16.28 million and $US63.27 million for the year.
The company has drawn debt of $US90 million and undrawn debt of $US40 million, mainly from facilities with NovaQuest and Oaktree Capital Management.
Believe us – these arrangements are a tad more complicated than ‘we lend, you pay us back’: the Oaktree facility involves the issue of warrants, while the NovaQuest tranche is only paid back after the GvHD drug is on the market.
Replenished by the April raising, Mesoblast had end-of-quarter cash of $US71.3 million. Dr Itescu now suggests that in order to preserve funds, the new GvHD trial will be prioritised over the back and heart programs.
Mesoblast shares peaked at $9.30 in October 2011, briefly rendering Mesoblast the most valuable ASX biotech with a $2.7 billion market capitalisation.
The stock today traded as low as 46 cents, just off the May 2005 record low of 39 cents.
In Mesoblast’s 2004 IPO prospectus the board noticed – presciently – that the $21 million raised “clearly… would not be sufficient to deliver regulatory approval to sell the products.”
As of June 2022, the AFR claimed the company had raised a staggering $US717 million.
The prospectus also envisaged a drug application being lodged within two to three years, which means the company remains about two decades behind schedule.
We guess that will make victory all the sweeter when a Mesoblast therapy is approved but investors rightly question whether this majestic day will arrive for the accident-prone (or unlucky) company.
Dr Itescu argues the company was always going to do an adult trial at around this time, but obviously wanted the paediatric product launched first.
In a revenue sense, GvHD approval for kids alone would not have been exactly company-making, with broker Bell Potter estimating peak sales of $US137 million.
But in terms of validating the company’s science and product pipeline, an FDA tick of approval would have been priceless.
Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. His Go Fund Me efforts to date have failed to raise $US717 million.
This column first appeared in Biotech Daily